Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02

Journal of Clinical Oncology

Volumn 21, Issue 21, 2003, Pages 3972-3978

  Hanks, Gerald E ^a   Pajak, Thomas F ^a   Porter, Arthur ^a   Grignon, David ^a   Brereton, Harmart ^a   Venkatesan, Varagur ^a   Horwitz, Eric M ^a   Lawton, Colleen ^a   Rosenthal, Seth A ^a   Sandler, Howard M ^a   Shipley, William U ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTAMIDE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADULT; AGED; CANCER STAGING; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; GOSERELIN; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; RADIATION DOSAGE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0642311912     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.11.023     Document Type: Article

References (18)

1. Pilepich MV, Krall JM, Al-Sarraf M, et al: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45:616-623, 1995
2. Pilepich MV, Caplan R, Byhardt RW, et al: Phase III trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of RTOG 85-31. J Clin Oncol 15:1013-1021, 1997
3. Pilepich M, Winter K, Lawton C, et al: Phase III trial of androgen suppression adjuvant to definitive radiotherapy: Long term results of RTOG study 85-31. J Clin Oncol 22:281, 2003
4. Hanks G, Lu J, Machtay M, et al: RTOG Protocol 92-02: A phase III trial of the use of long-term total androgen suppression following neoadjuvant cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 48:112, 2000
5. Lachin JM, Foulkes MA: Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 42:507-519, 1986
6. Zelen M: The randomization and stratification of patients to clinical trials. J Chronic Dis 27:365-375, 1974
7. Cox J, Grignon D, Kaplan R, et al: Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37:1035-1041, 1997
8. Cox JD, Stetz J, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 32:567-576, 1995
9. Kaplan, EL, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53:447-457, 1958
10. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
11. Kalbfleish JD, Prentice RL: The statistical analysis of failure times data. New York, NY, John Wiley, 1980
12. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
13. Pajak TF, Laramore GE, Marcial VA, et al: Elapsed treatment days: A critical item for radiotherapy quality control review in head and neck trials-RTOG report. Int J Radiat Oncol Biol Phys 20:13-20, 1991
14. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300, 1997
15. Bolla M, Collette L, Blank L, et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360:103-106, 2002
16. Hanks G, Hanlon A, Pinover W, et al: Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 46:823-832, 2000
17. Pollack A, Zagars G: External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys 39:1011-1018, 1997
18. Hanks G, Hanlon A, Pinover W et al: Survival advantage for prostate cancer patients treated with high dose 3D conformal radiation. Cancer J Sci Am 5:152-158, 1999